Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/114730
DC Field | Value | Language |
---|---|---|
dc.contributor.author | González Villa, Isabel | en_US |
dc.contributor.author | González Dávila, Enrique Francisco | en_US |
dc.contributor.author | Expósito Afonso, Idaira Jael | en_US |
dc.contributor.author | Martínez Blanco, Leynis Isabel | en_US |
dc.contributor.author | Loro Ferrer, Juan Francisco | en_US |
dc.contributor.author | Cabrera Galván, Juan José | en_US |
dc.date.accessioned | 2022-05-16T14:10:47Z | - |
dc.date.available | 2022-05-16T14:10:47Z | - |
dc.date.issued | 2022 | en_US |
dc.identifier.issn | 1699-048X | en_US |
dc.identifier.other | Scopus | - |
dc.identifier.uri | http://hdl.handle.net/10553/114730 | - |
dc.description.abstract | Purpose: In endometrial cancer, the incidence of mutations in mismatch repair genes (MMR) is estimated at 17–30%. Patients with alterations at this level (MSI) are known to have different clinical and anatomopathological characteristics than those without this genetic alteration (MSS). In this study, we aim to identify the MSI phenotype in patients who underwent hysterectomy for endometrial cancer. We assessed the correlation of this phenotype with anatomoclinical parameters such as obesity and histological subtype. Methods/patients: Clinical and anatomopathological data were collected from 147 patients diagnosed with endometrial cancer and an immunohistochemical study of MMR system proteins was performed. PMS2 and MSH6 proteins were evaluated as primary screening and subsequent evaluation of MLH1 and MSH6, respectively, if the former were negative. Statistical association between the anatomopathological data and the immunohistochemical result was analyzed. Results and conclusions: 22.4% of our patients were MSI phenotype. We obtained statistically significant differences by multivariate analysis between endometrioid subtype and higher FIGO classification grade with MSI phenotype and obesity with MSS phenotype. Given these statistical results, we propose a function for predicting the probability of being MSI phenotype taking into account the histological subtype (endometrioid/non-endometrioid carcinoma) and FIGO grade as well as obesity. This prediction may be useful prior to hysterectomy, for genetic study of the MLH1 promoter and subsequent genetic counseling. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Clinical and Translational Oncology | en_US |
dc.source | Clinical and Translational Oncology[ISSN 1699-048X], (Mayo 2022) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 320101 Oncología | en_US |
dc.subject.other | Body Mass Index | en_US |
dc.subject.other | Dna Mismatch Repair Deficiency | en_US |
dc.subject.other | Endometrial Neoplasms | en_US |
dc.subject.other | Immunohistochemistry | en_US |
dc.subject.other | Msi Phenotype | en_US |
dc.title | An effective algorithm to detect the possibility of being MSI phenotype in endometrial cancer given the BMI status and histological subtype: a statistical study | en_US |
dc.type | info:eu-repo/semantics/workingPaper | en_US |
dc.type | workingPaper | en_US |
dc.identifier.doi | 10.1007/s12094-022-02837-4 | en_US |
dc.identifier.scopus | 85129371124 | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | 0000-0002-0781-9161 | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | 0000-0002-0517-8209 | - |
dc.contributor.orcid | 0000-0002-4184-6403 | - |
dc.contributor.authorscopusid | 57203820230 | - |
dc.contributor.authorscopusid | 23988717000 | - |
dc.contributor.authorscopusid | 57665929400 | - |
dc.contributor.authorscopusid | 57666877200 | - |
dc.contributor.authorscopusid | 57667188800 | - |
dc.contributor.authorscopusid | 55583643400 | - |
dc.identifier.eissn | 1699-3055 | - |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo preliminar | en_US |
dc.description.numberofpages | 9 | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Mayo 2022 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 0,831 | |
dc.description.jcr | 3,4 | |
dc.description.sjrq | Q2 | |
dc.description.jcrq | Q3 | |
dc.description.scie | SCIE | |
dc.description.miaricds | 10,8 | |
item.grantfulltext | open | - |
item.fulltext | Con texto completo | - |
crisitem.author.dept | GIR IUIBS: Bioquímica | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Clínicas | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.orcid | 0000-0002-0517-8209 | - |
crisitem.author.orcid | 0000-0002-4184-6403 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | González Villa, Isabel | - |
crisitem.author.fullName | Expósito Afonso, Idaira Jael | - |
crisitem.author.fullName | Loro Ferrer, Juan Francisco | - |
crisitem.author.fullName | Cabrera Galván,Juan José | - |
Appears in Collections: | Artículo preliminar |
SCOPUSTM
Citations
2
checked on Dec 8, 2024
WEB OF SCIENCETM
Citations
2
checked on Dec 8, 2024
Page view(s)
98
checked on Mar 16, 2024
Download(s)
37
checked on Mar 16, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.